Dendrites 20synapses
Moleculera logo cmyk

Moleculera Labs, Inc.

A neuroimmunology diagnostics company focused on changing how medicine is practiced for neuropsychiatric and behavioral disorders

  • Stage Full Product Ready
  • Industry Healthcare Services
  • Location Oklahoma City, OK, USA
  • Currency USD
  • Founded September 2011
  • Employees 15
  • Incorporation Type C-corp
  • Website

Company Summary

60MM Americans suffer from neuropsychiatric and developmental disorders treated with neuropsychiatric drugs, often with little improvement. We are a precision medicine company directing treatment to an underlying immune dysfunction. Patients experience remarkable recoveries when properly diagnosed and treated. These include PANDAS/PANS, autism, ADD/ADHD, anxiety disorder and others. Generating $7.5MM in cumulative revenue on $5.5MM investment.


  • Shimasaki 20headshot 20v2
    President & CEO

    33 years biotechnology industry experience beginning at Genentech; serial entrepreneur co-founding 9 companies in molecular testing, diagnostic/medical device and therapeutics, led 5 products through FDA 510(k), taking several companies public. PhD in Molecular Biology and Biotechnology, MBA from Northwestern University’s Kellogg School of Business.

  • E82b7f43 1cbf 4a44 b570 4db9cf3738c2
    Chief Scientific Officer

    OUHSC George Lynn Cross Research Professor, over 40 years research in molecular mimicry and immunity, inventor of technology. Over 100+ peer-reviewed publications in high impact journals such as Nature Medicine, Journal of Immunology, Journal of Clinical Microbiology, Neuropsychopharmacology.

  • 45+ years experience in corporate finance and accounting, Began career at Touche Ross & Co. in 1962. Controller at Elgin National & Columbia Pictures, CFO at Wilkinson Sword, Financial consultant to numerous companies including two biotechnology companies including one publicly traded biotechnology company.

  • 9a9d0147 5adb 4854 aff3 dc2140df989b
    VP of Research & Clinical Development (Consultant)

    30+ years experience in building successful diagnostic and therapeutic companies from company inception through successful exits, including a $230M exit to Roche. Ph.D. in Biochemistry from Oklahoma State University and postdoctoral training at Dartmouth Medical School.

  • B9a4e6bf 3a5b 4d2e b453 ca3f7d3f06f9
    VP of Commercial Development (Consultant)

    30 years life science product commercialization in start-ups, a mid-cap and 3 Fortune 500 companies. Management of marketing and sales teams for Johnson & Johnson, Abbott Diagnostics and Cordis Cardiology. Directed marketing Becton Dickinson’s $210M molecular diagnostics business.


Previous Investors

  • Default avatar
    Innovation to Enterprise (i2E)
    Default avatar
    SeedStep Angels and Local Investors
    Default avatar
    Dr. Brian Clevinger, Prolog Ventures
    Managing Director
  • Default avatar
    Dr. Robert Calcaterra